

# International Spotlights & Policy

## Spotlight on the BRICs:

# RUSSIA



MINISTRY OF **INDUSTRY AND TRADE**  
OF THE RUSSIAN FEDERATION

[www.minpromtorg.gov.ru](http://www.minpromtorg.gov.ru)



Ministry of Economic Development  
of The Russian Federation

[www.economy.gov.ru](http://www.economy.gov.ru)

### Organizers:



### Supported by



**Session ID: 2014**  
**Location Building: S102 A**

8:30–9:15 a.m.

## Welcome & Keynote Presentation

**Rogério Ribeiro**, *Vice President, Emerging Markets, GSK*

**Nikolay Gerasimenko**, *First Deputy Chairman, Committee on Health, State Duma of the Russian Federation*

**Valeriy Chereshev**, *Chairman, Committee on Science & Innovations, State Duma of the Russian Federation*

9:15–10:30 a.m.

## Pharma2020. Russia's Transformation From Emerging to One of the Fastest Growing Pharmaceutical Markets

Government support and initiatives are critical to creating an ideal environment for a country to grow as a biopharmaceutical hub. Russia is striving to reach the goals set by the Russian government in its Pharma2020 program. This interactive panel will discuss the first results of Pharma2020. Speakers will cover the following topics: Changes in the Russian Regulatory System; First Results of the Federal Program's Implementation; Main Factors Contributing to the High Growth of the Russian Pharmaceutical Market; How the Phenomenon of 'reverse innovation' can help Maximize Pharma Opportunities in High Growth Markets; and WTO's Impact on the Russian Pharmaceutical Market. Major deals concluded between Big Pharma and Russian companies will be highlighted. Session attendees will learn more about existing opportunities available for international partnerships within the Russian market. Executives from pharmaceutical companies operating in Russia, as well as the government officials, will be present to provide additional 'expert' commentary.

**Moderator: Wendy Diller**, *Chief, Business Bureau, Biopharma Group Elsevier Business Intelligence*

### Speakers:

**Yury Sluysar**, *Deputy Minister, Ministry of Industry and Trade, Russia*

**Sergey Tsyb**, *Head of the Department, Ministry of Industry and Trade, Russia*

**Andrey Ivashchenko**, *Chairman of the Board, ChemRar High Tech Center, Russia*

**Alexey Repik**, *Chairman of the Board at R-Pharm, Russia*

**Alberto Colzi**, *Divisional Vice President, AbbVie, USA*

### Panel of experts:

**Oleg Demidov**, *Department for innovations and high technology, Vnesheconombank*

**Rogério Ribeiro**, *VP of Emerging Markets, GSK*

**Prof. Konstantin Skryabin**, *Director of the Centre "Bioengineering" Russian Academy of Sciences*

**Dmitry Kuzmin**, *UK Partner, RVC*

**Petr Rodionov**, *CEO of Geropharm*

10:45 a.m.–12:00 p.m.

## The Role of Biopharm Clusters in the Modernization and Technological Development of the Russian Economy

In the past five years, significant efforts have been provided to stimulate Russia's technological growth. The panel will examine the role of the Russian government and the private sector in promoting local innovation and creating an integrated Biopharma ecosystem. The Russian government actively provides state financial support, institutional grants and portfolio investments in venture funds. A number of government programs, including the Ministry of Economic Development initiatives, provide participants with access to the most advanced scientific and educational resources and funding for state-of-the-art bioindustrial cluster infrastructure in order to create more favorable conditions for high-tech innovation. Private capital and industry work closely to create the instruments of the venture financing, build product focused R&D and manufacturing with regional and global market access. Academia, educational and applied research institutions provide sources of IP and human capital, serve as a «baseboard» for public-private partnerships, and coordinate public instruments with private interests and money. The most successful examples of such cooperation between local governments, entrepreneurs, and international pharmaceutical companies will be discussed by key participants during this interactive session. Speakers and experts will be represented by federal and regional government authorities, state development institutions, executives from pharm-, bio- and medical clusters, representatives of the international pharmaceutical companies and research scientists.

**Moderator: Marina Bozilenko**, *Head of Biotechnology & Pharma, William Blair & Company, LLC*

### Speakers:

**Oleg Fomichev**, *Deputy Minister of Economic Development, Russia*

**Nikolay Savchuk**, *Director of the Center for Strategic Development, Moscow Institute of Physics and Technology*

**Ivan Bortnik**, *Executive Director of the Association of Innovative Regions of Russia*

**Igor Agamirzyan**, *CEO of RVC*

**Anna Protopapas**, *Executive VP Global Business Development, Takeda, USA*

### Panel of experts:

**Sergey Yastrebov**, *Governor of Yaroslavl region, Russia*

**Oleg Korzinov**, *Executive Director of BiopharmCluster "Northern", Russia*

**Marek Dziki**, *Executive Director of Biomed cluster Skolkovo, Russia*

**Zakhar Golant**, *Chairman of "Medical and pharmaceutical projects. XXI century", NCP, Russia*

**Fabrice Egros**, *Sr. Executive director, Novamedica, Russia*

**Dmitry Kulish**, *Executive Vice President, Nanolek, Russia*

**Simon Sturge**, *Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim*